Lantern Pharma Completes FDA Type C Meeting for Planned Pediatric CNS Cancer Trial
Lantern Pharma Inc., an AI-driven clinical-stage oncology company, announced the successful completion of a Type C meeting with the U.S. Food and Drug Administration (FDA). The meeting provided guidance on the regulatory pathway and design of a planned pediatric trial for central nervous system (CNS) cancers, including Atypical Teratoid Rhabdoid Tumor (ATRT). The FDA supported Lantern’s proposed trial structure, which includes a parallel ATRT cohort to accelerate data collection, and confirmed the potential use of spironolactone as a combination agent with Lantern’s lead therapy, LP-184/STAR-001.
Lantern Pharma Completes FDA Type C Meeting for Planned Pediatric CNS Cancer Trial